WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech”, "Kane” or the "Company”) today announces that Health Canada has approved its revyve® Antimicrobial ...
WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ ...
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces ...
For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical meetings in 2025 and 2026. “Interest from clinicians and ...
The global Antimicrobial Wound Care Dressings Market is expected to be worth US$ 1.38 billion in 2023, with a CAGR of 6.4% from 2023 to 2033. By 2033, the global market is set to reach US$ 2.57 ...
“Kane has taken their revyve™ Antimicrobial Wound Gel and loaded it into this new, patent-pending delivery system creating a highly differentiated product ideal for burns and other sensitive wounds”, ...
"Interest from clinicians and patients in the U.S. case series is encouraging,” said Dr. Robert Huizinga, Interim CEO. "revyve products can meaningfully improve outcomes for those suffering from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback